Boston Scientific Corp. (BSX) Financials
Key financial figures for Boston Scientific Corp. (Q2 2026).
Boston Scientific grew net sales 7.5% to $5.442 billion in Q2 2026 and beat its own adjusted EPS guidance with $0.86, but cut full-year 2026 organic growth guidance again, to 5-6% from 6.5-8.0%. Net sales reached $5.442 billion, up 7.5% reported and 7.0% organic versus Q2 2025 Adjusted EPS of $0.86 beat the company's own guidance range of $0.82 to $0.84; GAAP diluted EPS was $0.61 on GAAP net income of $907 million Cardiovascular segment sales rose 8.3% reported (7.8% organic) to $3.624 billion, led by continued FARAPULSE electrophysiology and TAVR strength MedSurg segment sales rose 5.9% reported (5.4% organic) to $1.818 billion Growth was broad-based geographically: U.S. On the outlook: Full-year 2026 net sales growth guidance lowered to approximately 5.5-6.5% reported (5-6% organic), down from the prior 6.5-8.0% organic guide, with full-year adjusted EPS narrowed to $3.28-$3.32 from $3.34-$3.41; Q3 2026 net sales growth guided to approximately 3-5% reported and organic, with Q3 adjusted EPS of $0.80-$0.82. Figures are for Q2 2026, as Boston Scientific Corporation reported them.
- Revenue
- $5.4B
- Net Income
- $905M
- EPS
- $0.62
- Total Assets
- $45.2B
- Operating Cash Flow
- $1.5B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $5.4B | $907M | $0.61 | 21.65% | $1.3B |
| Q1 FY2026 | $5.2B | $1.3B | $0.90 | 20.6% | $171M |
| Q4 FY2025 | $5.3B | $668M | $0.45 | 22.81% | $1.0B |
| Q3 FY2025 | $5.1B | $755M | $0.50 | 20.73% | $1.2B |
| Q2 FY2025 | $5.1B | $793M | $0.53 | 16.18% | $1.1B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $20.1B | $2.9B | $1.94 | 19.78% | $3.7B |
| FY2024 | $16.7B | $1.9B | $1.25 | 15.73% | $2.6B |
| FY2023 | $14.2B | $1.6B | $1.07 | 15.32% | $1.7B |
Frequently asked questions
What was Boston Scientific Corporation's revenue last quarter?
Boston Scientific Corporation reported revenue of $5.44 billion for Q2 FY2026, up 7.5% from the same period a year earlier.
Is Boston Scientific Corporation profitable?
Yes. Boston Scientific Corporation reported net income of $907.0 million for Q2 FY2026, a net margin of 16.67% on revenue.
How has Boston Scientific Corporation's margin trended?
Operating margin was 21.65% in Q2 FY2026, compared with 16.18% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Boston Scientific Corporation generate?
Boston Scientific Corporation generated free cash flow of $1.28 billion in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Boston Scientific Corp. on SentiSense, with up to forty quarters and twenty fiscal years of history.